透析療法ネクスト　XXI

出版社： 医学図書出版
著者：
発行日： 2017-02-28
分野： 臨床医学：内科  >  腎臓
ISBN： 9784865171983
電子書籍版： 2017-02-28
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,850 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,310 円(税込)

購入する

商品紹介

シリーズ第21弾！「透析患者におけるHCV治療の新たなる展開―透析患者もC型肝炎が治る時代に―」と題し、特集・座談会を収載しています。

目次

  • 透析療法ネクスト　XXI

    ―目次―

    座談会
    ■透析患者におけるHCV 治療の新たな展開

    特集　透析患者におけるHCV 治療の新たなる展開
    　　　―透析患者もC 型肝炎が治る時代に―
    ■1．HCV とは
    1．HCV とは
    2．HCV 感染が患者にもたらす不利益
    3．C 型肝炎ウイルス駆逐療法の意図
    ■2．HCV 感染透析患者の現況と対策
    はじめに
    1．HCV 感染透析患者の生命予後
    2．HCV 感染と腎移植
    3．腎機能正常者における抗ウイルス療法
    4．透析患者における抗ウイルス療法
    5．透析患者への抗ウイルス療法の実際
    6．血液透析施設でのB 型肝炎、C 型肝炎への対策
    おわりに
    ■3．透析患者におけるHCV1 型治療
    　　1）治療法
    はじめに
    1．透析患者に対する慢性C 型肝炎治療の治療適応と注意点
    2．透析症例に対するC 型肝炎治療
    おわりに
    　　2）ダクラタスビル＋アスナプレビル併用療法使用経験
    はじめに
    1．対象および方法
    2．成績
    3．考案
    最後に
    　　3）ダクラタスビル＋アスナプレビル併用療法使用経験
    　　　　薬物動態からみた有効性および安全性について
    はじめに
    1．試験デザイン
    2．対象と患者背景
    3．併用薬
    4．薬物動態
    5．有効性について
    6．安全性について
    7．考察
    まとめ
    　　4）ダクラタスビル＋アスナプレビル併用療法使用経験
    はじめに
    1．対象・方法
    2．結果
    3．考察
    おわりに
    　　5）Genotype 1 型C 型慢性肝炎に対する
    　　　　ヴィキラックス配合錠(R)の使用経験
    はじめに
    1．対象
    2．方法
    3．結果
    4．考察
    おわりに
    　　6）透析患者におけるHCV 治療の新たなる展開
    　　　　─ C-SURFER 試験─
    背景
    1．方法
    2．結果
    3．結論
    4．コメント
    ■4．HCV 治療を積極的に進めていくためには
    はじめに
    1．透析医と肝臓医の協力体制
    2．院内感染対策としてのメリット
    3．医療経済
    おわりに

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

座談会

P.6 掲載の参考文献
1) 小高道夫 : 透析会誌 21 (1), 1-39, 1988
 
2) 日本透析医学会統計調査委員会 : 「図説わが国の慢性透析療法の現状 2007年12月31日現在」, 2008
 
3) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : 「C型肝炎治療ガイドライン (第5.1版)」, 2016
 
4) Tanaka J, et al : Intervirology 54 (4), 185-195, 2011
PubMed
5) Iwasa Y, et al : Clin Exp Nephrol 12 (1), 53-57, 2008
PubMed
6) Nakayama E, et al : J Am Soc Nephrol 11 (10), 1896-1902, 2000
PubMed
7) 菊地勘 : 臨牀透析 30 (7), 112-122, 2014
 
8) 日本透析医学会統計調査委員会. 「図説わが国の慢性透析療法の現状 2014年12月31日現在」, 2015
 
9) 田端秀日朗他 : 透析会誌 45 (12), 1147-1153, 2012
 
10) 日本透析医学会, 透析会誌 44 (6), 481-531, 2011
 
11) Kikuchi K, et al : Ther Apher Dial 18 (6), 603-611, 2014
PubMed
12) Suda G, et al : J Gastroenterol 51 (7), 733-740, 2016
PubMed
13) Roth D, et al : Lancet 386 (10003), 1537-1545, 2015
PubMed
14) 小川栄一 : 感染症誌 89 (1), 1-9, 2015
 

特集 透析患者におけるHCV治療の新たなる展開 - 透析患者もC型肝炎が治る時代に -

P.12 掲載の参考文献
1) Tanaka J, Kumagai J, Katayama K, et al : Sex-and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3, 485, 648 first-time blood donors during 1995-2000. Intervirology 47 : 32-40, 2004
 
2) 田中順子 : HCV感染の疫学・感染経路. 榎本信幸, 竹原徹郎, 持田智編. C型肝炎の診療を極める 基本から最前線まで. 文光堂, 東京, p15-22, 2014
 
3) 中沼安二 : ウイルス性肝炎 : 急性肝炎と慢性肝炎/肝硬変. 中沼安二編. 肝臓を診る医師のための肝臓病理テキスト. 南江堂, 東京, p74-88, 2013
 
4) 中沼安二 : 肝. 向井清, 真鍋俊明, 深山正久編. 外科病理学 第4版. 文光堂, 東京, p599-664, 2006
 
5) 佐々木素子, 中沼安二 : 病理診断. 榎本信幸, 竹原徹郎, 持田智編. C型肝炎の診療を極める 基本から最前線まで. 文光堂, 東京, p67-72, 2014
 
6) Kanda T, Yokosuka O, Imazeki F, et al : Acute hepatitis C virus infection, 1986-2001 : a rare cause of fulminant hepatitis in Chiba, Japan. Hepatogastroenterology 51 : 556-558, 2004
PubMed
7) Seeff LB : Natural history of chronic hepatitis C. Hepatology 36 : S35-46, 2002
PubMed
8) Wu S, Kanda T, Nakamoto S, et al : Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients : ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One 8 : e73615, 2013
PubMed
9) 神田達郎, 横須賀収 : C型肝炎診断の基本 (病態, 予後, 治療). 榎本信幸, 竹原徹郎, 持田智編. C型肝炎の診療を極める 基本から最前線まで. 文光堂, 東京, p40-44, 2014
 
10) Prati D, Taioli E, Zanella A, et al : Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 : 1-10, 2002
PubMed
11) Sandrin L, Fourquet B, Hasquenoph JM, et al : Transient elastography : a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29 : 1705-1713, 2003
PubMed
12) Takahashi H, Ono N, Eguchi Y, et al : Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease : a pilot study. Liver Int 30 : 538-545, 2010
PubMed
13) Koizumi Y, Hirooka M, Kisaka Y, et al : Liver fibrosis in patients with chronic hepatitis C : noninvasive diagnosis by means of real-time tissue elastography-establishment of the method for measurement. Radiology 258 : 610-617, 2011
PubMed
14) Ichikawa S, Motosugi U, Ichikawa T, et al : Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C. Magn Reson Med Sci 11 : 291-297, 2012
PubMed
15) 伊藤清顕 : 肝線維化マーカー. 榎本信幸, 竹原徹郎, 持田智編. C型肝炎の診療を極める基本から最前線まで. 文光堂, 東京, p84-88, 2014
 
16) Ito K, Kuno A, Ikehara Y, et al : Lec T-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 56 : 1448-1456, 2012
 
17) Wai CT, Greenson JK, Fontana RJ, et al : A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 : 518-526, 2003
PubMed
18) Vallet-Pichard A, Mallet V, Nalpas B, et al : FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 46 : 32-36, 2007
PubMed
19) Wang CC, Krantz E, Klarquist J, et al : Acute hepatitis C in a contemporary US cohort : modes of acquisition and factors influencing viral clearance. J Infect Dis 196 : 1474-1482, 2007
 
20) 渡辺久剛, 上野義之 : C型肝炎の自然経過. 榎本信幸, 竹原徹郎, 持田智編. C型肝炎の診療を極める 基本から最前線まで. 文光堂, 東京, p23-31, 2014
 
21) Leandro G, Mangia A, Hui J, et al : Relationship between steatosis, inflammation and fibrosis in chronic hepatitis C : a meta-analysis of individual patient data. Gastroenterology 130 : 1636-1642, 2006
PubMed
22) Naing C, Mak JW, Ahmed SI, et al : Relationship between hepatitis C virus infection and type 2 diabetes mellitus : meta-analysis. World J Gastroenterol 18 : 1642-1651, 2012
PubMed
23) Miyanari Y, Atsuzawa K, Usuda N, et al : The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9 : 1089-1097, 2007
PubMed
24) Perlemuter G, Sabile A, Letteron P, et al : Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion : a model of viral-related steatosis. FASEB J 16 : 185-194, 2002
 
25) Furutani T, Hino K, Okuda M, et al : Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130 : 2087-2098, 2006
PubMed
26) 第19回全国原発性肝癌追跡調査報告. p45, 2014
 
27) Asahina Y, Tsuchiya K, Nishimura T, et al : α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 58 : 1253-1262, 2013
 
28) Fujita N, Sugimoto R, Motonishi S, et al : Patients with chronic hepatitis C achieving asustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 49 : 702-710, 2008
PubMed
29) Fujita N, Horiike S, Sugimoto R, et al : Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med 42 : 353-362, 2007
PubMed
30) Kasahara A, Tanaka H, Okanoue T, et al : Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 11 : 148-156, 2004
 
31) Yoshida H, Arakawa Y, Sata M, et al : Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123 : 483-491, 2002
PubMed
32) Tachi Y, Hirai T, Miyata A, et al : Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res 45 : 238-246, 2015
PubMed
33) Morgan RL, Baack B, Smith BD, et al : Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma : ameta-anaiysis of observational studies. Ann Intern Med 158 : 329-337, 2013
 
P.20 掲載の参考文献
1) 日本透析医学会統計調査委員会編 : 図説わが国の慢性透析療法の現況2007年12月31日現在. 東京 : 日本透析医学会, 2008
 
2) Nakai S, Suzuki K, Masakane I, et al : Over-view of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial 14 : 505-540, 2010
 
3) Nakayama E, Akiba T, Marumo F, et al : Prognosis of Anti-Hepatitis C Virus Anti-body-Positive Patients on Regular Hemodialysis Therapy. J Am Soc Nephrol 11 : 1896-1902, 2000
 
4) 田端秀日朗, 菊地勘, 石田英樹, 他 : 生体腎移植でのHCV抗体陽性レシピエントにおける腎生着率と生存率の検討. 透析会誌 45 : 1147-1153, 2012
 
5) Kumada H, Suzuki Y, Ikeda K, et al : Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59 : 2083-2091, 2014
PubMed
6) Mizokami M, Yokosuka O, Takehara T, et al : Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial. Lancet Infect Dis 15 : 645-653, 2015
 
7) Kumada H, Chayama K, Rodrigues L Jr, et al : Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 62 : 1037-1046, 2015
 
8) 社団法人日本透析医学会透析患者のC型ウイルス肝炎治療ガイドライン作成ワーキンググループ : 透析患者のC型ウイルス肝炎治療ガイドライン. 透析会誌 44 : 481-531, 2011
 
9) Kikuchi K, Akiba T, Nitta K, et al : Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis : REACH study. Ther Apher Dial 18 : 603-611, 2014
 
10) 日本透析医会, 日本透析医学会, 日本臨床工学技士会, 他 : 透析施設における標準的な透析操作と感染予防に関するガイドライン (四訂版). 東京 : 日本透析医会, 2015
 
P.25 掲載の参考文献
1) Kidney Disease : Improving Global Outcomes : KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 109 : S1-99, 2008
PubMed
2) Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al : High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied. Clin Nephrol 54 : 151-156, 2000
PubMed
3) Nakayama E, Akiba T, Marumo F, et al : Prognosis of anti-hepatitis C virus antibodypositive patients on regular hemodialysis therapy. J Am Soc Nephrol 11 : 1896-1902, 2000
PubMed
4) Merck & Co. I. REBETOL(R) (ribavirin USP) capsules, for oral use : PRESCRIBING INFORMATION 2016
 
5) Gordon CE, Uhlig K, Lau J, et al : Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection : a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 51 : 263-277, 2008
PubMed
6) Fabrizi F, Dixit V, Messa P, et al : Pegylated Interferon Mono-Therapy of Chronic Hepatitis C in the Dialysis Population : Systematic Review and Meta-Analysis. Ther Apher Dial 19 : 611-621, 2015
 
7) Kikuchi K, Akiba T, Nitta K et al : Multicenter study of pegylated interferon alpha-2a monotherapy for hepatitis C virus-infected patients on hemodialysis : REACH study. Ther Apher Dial 18 : 603-611, 2014
PubMed
8) Mizokami M, Yokosuka O, Takehara T, et al : Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial. Lancet Infect Dis 15 : 645-653, 2015
PubMed
9) Omata M, Nishiguchi S, Ueno Y, et al : Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection : an open-label, phase 3 trial. J Viral Hepat 21 : 762-768, 2014
 
10) Kumada H, Hayashi N, Izumi N, et al : Simeprevir (TMC435) once daily with peginterferon-alpha-2b and ribavirin in patients with genotype 1 hepatitis C virus infection : The CONCERTO-4 study. Hepatol Res 45 : 501-513, 2015
PubMed
11) Poordad F, Hezode C, Trinh R, et al : ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370 : 1973-1982, 2014
PubMed
12) Company B-MS : Sunvepra Capsules (asunaprevir) Japanese Prescribing Information. 2014
 
13) Company B-MS : Daklinza Tablets (daclatasvir) Japaese Prescibing Information 2014. 2014
 
14) Company B-MS : Sunvepra Capsules (Asunaprevir) Japanese Prescribing Information. 2014
 
15) Suda G, Kudo M, Nagasaka A, et al : Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 51 : 733-740, 2016
PubMed
16) Toyoda H, Kumada T, Tada T, et al : Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 51 : 741-747, 2016
PubMed
17) Roth D, Nelson DR, Bruchfeld A, et al : Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) : a combination phase 3 study. Lancet 386 : 1537-1545, 2015
 
18) Pockros PJ, Reddy KR, Mantry PS, et al : Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology 150 : 1590-1598, 2016
PubMed
P.31 掲載の参考文献
1) Mohd Hanafiah K, Groeger J, Flaxman AD, et al : Global epidemiology of hepatitis C virus infection : new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 : 1333-1342, 2013
PubMed
2) Kumada H, Suzuki Y, Ikeda K, et al : Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59 : 2083-2091, 2014
PubMed
3) Fissell RB, Bragg-Gresham JL, Woods JD, et al : Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents : the DOPPS. Kidney Int 65 : 2335-2342, 2004
PubMed
4) 社団法人日本透析医学会 : 透析患者のC型ウイルス肝炎治療ガイドライン. 透析会誌 44 : 481-531, 2011
 
5) Fabrizi F, Martin P, Dixit V, et al : Hepatitis C virus antibody status and survival after renal transplantation : meta-analysis of observational studies. Am J Transplant 5 : 1452-1461, 2005
PubMed
6) Garimella T, Wang R, Luo WL, et al : Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther 20 : 535-543, 2015
PubMed
7) Garimella T, He B, Luo WL, et al : Asunaprevir pharmacokinetics and safety in subjects with impaired renal function. Hepatology 58 : 430A, 2013
 
8) Toyoda H, Kumada T, Tada T, et al : Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 51 : 741-747, 2016
PubMed
9) Liu CH, Liu CJ, Huang CF, et al : Pegylated interferon-a2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis : A randomized trial. Ann Intern Med 159 : 729-738, 2013
PubMed
10) Deltenre P, Moreno C, Tran A, et al : Antiviral therapy in haemodialysed HCV patients : efficacy, tolerance and treatment strategy. Aliment Pharmacol Ther 34 : 454-461, 2011
PubMed
11) Suda G, Kudo M, Nagasaka A, et al : Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 51 : 733-740, 2016
PubMed
12) Kawakami Y, Imamura M, Ikeda H, et al : Pharmacokinetics, eihcacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C : pilot study. J Viral Hepat 23 : 850-856, 2016
PubMed
13) Miyazaki R, Miyagi K : Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b-Infected Patients on Hemodialysis. Ther Apher Dial 20 : 462-467, 2016
PubMed
14) Nakayama E, Akiba T, Marumo F, et al : Prognosis of anti-hepatitis C virus anti-bodypositive patients on regular hemodialysis therapy. J Am Soc Nephrol 11 : 1896-1902, 2000
 
15) Ohsawa M, Kato K, Tanno K, et al : Seropositivity for anti-HCV core antigen is independently associated with increased allcause, cardiovascular, and liver diseaserelated mortality in hemodialysis patients. J Epidemiol 21 : 491-499, 2011
PubMed
P.39 掲載の参考文献
1) Kumada H, Suzuki Y, Ikeda K, et al : Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59 : 2083-2091, 2014
PubMed
2) Kawakami Y, Imamura M, Ikeda H, et al : Pharmacokinetics, ef6cacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C : pilot study. J Viral Hepat 23 : 850-856, 2016
PubMed
P.46 掲載の参考文献
1) 中井滋, 政金生人, 重松隆他 : わが国の慢性透析療法の現況 (2007年12月31日現在). 透析会誌 42 : 1-45, 2009
 
2) Kwon E, Cho JH, Jang HM, et al : Differential Effect of Viral Hepatitis Infection on Mortality among Korean Maintenance Dialysis Patients : A Prospective Multicenter Cohort Study. PLoS One 10 : e0135476, 2015
PubMed
3) Nakayama E, Akiba T, Marumo F, et al : Prognosis of anti-hepatitis C virus antibodypositive patients on regular hemodialysis therapy. J Am Soc Nephrol 11 : 1896-1902, 2000
PubMed
4) Di Napoli A, Pezzotti P, Di Lallo D, et al : Epidemiology of hepatitis C virus among long-term dialysis patients : a 9-year study in an Italian region. Am J Kidney Dis 48 : 629-637, 2006
 
5) Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al : Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 18 : 1584-1593, 2007
PubMed
6) Fabrizi F, Dulai G, Dixit V, et al : Metaanalysis : interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 18 : 1071-1081, 2003
PubMed
7) Fabrizi F, Dixit V, Messa P, et al : Interferon monotherapy of chronic hepatitis C in dialysis patients : meta-analysis of clinical trials. J Viral Hepat 15 : 79-88, 2008
PubMed
8) Ohsawa M, Kato K, Tanno K, et al : Seropositivity for anti-HCV core antigen is independently associated with increased allcause, cardiovascular, and liver diseaserelated mortality in hemodialysis patients. J Epidemiol 21 : 491-499, 2011
PubMed
9) Marinaki S, Boletis JN, Sakellariou S, et al : Hepatitis C in hemodialysis patients. World J Hepatol 7 : 548-558, 2015
PubMed
10) 秋葉隆, 日台英雄, 川口良人, 他 : 日本の慢性透析療法を行っている施設での院内感染防止の現況-院内感染防止に関する透析施設調査アンケートより. 透析会誌 28 : 847-856, 1995
 
11) Park H, Adeyemi A, Henry L, et al : A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Virai Hepat 22 : 897-905, 2015
 
12) Chen YC, Lin HY, Li CY, et al : Anationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 85 : 1200-1207, 2014
 
13) 日本透析医会, 日本透析医学会, 日本臨床工学技士会, 他 : 透析施設における標準的な透析操作と感染予防に関するガイドライン (四訂版). 2015. http://www.touseki-kai.or.jp/htm/07_manual/doc/20150512_infection_guideline_ver4.pdf
 
14) Kalantar-Zadeh K, McAllister CJ, Miller LG : Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients : a population based study. Nephrol Dial Transplant 20 : 1662-1669, 2005
PubMed
15) Kikuchi K, Akiba T, Nitta K, et al : Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis : REACH study. Ther Apher Dial 18 : 603-611, 2014
 
16) Kumada H, Suzuki Y, Ikeda K et al : Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59 : 2083-2091, 2014
PubMed
17) Kumada H, Chayama K, Rodrigues L Jr, et al : Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 62 : 1037-1046, 2015
 
18) Mizokami M, Yokosuka O, Takehara T, et al : Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial. Lancet Infect Dis 15 : 645-653, 2015
PubMed
19) Miyazaki R, Miyagi K : Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b-Infected Patients on Hemodialysis. Ther Apher Dial 20 : 462-467, 2016
PubMed
20) Suda G, Kudo M, Nagasaka A, et al : Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 51 : 733-740, 2016
PubMed
21) Toyoda H, Kumada T, Tada T, et al : Safety and eihcacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 51 : 741-747, 2016
PubMed
22) Roth D, Nelson DR, Bruchfeld A, et al : Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) : a combination phase 3 study. Lancet 386 : 1537-1545, 2015
 
23) 日本肝臓学会肝炎診療ガイドライン作成委員会 : C型肝炎治療ガイドライン (第5.2版). 2016. http://www.jsh.or.jp/files/uploads/HCV_GL_ver5.2_final_Dec13.pdf
 
24) Hill L : Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment. Top Antivir Med 23 : 92-96, 2015
PubMed
25) Poole RM : Daclatasvir＋Asunaprevir : First Global Approval. Drugs 74 : 1559-1571, 2014
PubMed
26) 公益財団法人ウイルス肝炎研究財団 : 平成28年C型慢性肝炎・肝硬変治療ガイドライン. http://www.vhfj.or.jp/04.support/
 
27) Bristol-Myers Squibb Company. Sunvepra Capsules (asunaprevir) Japanese Prescribing Information. 2014
 
28) Soriano V, Labarga P, Barreiro P, et al : Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol 11 : 333-341, 2015
PubMed
29) Asselah T, Boyer N, Saadoun D, et al : Directacting antivirals for the treatment of hepatitis C virus infection : optimizing current IFN-free treatment and future perspectives. Liver Int 36 : S47-57, 2016
 
P.54 掲載の参考文献
1) Kikuchi K Akiba T, Nitta K, et al : Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis : REACH study. Ther Apher Dial 18 : 603-611, 2014
 
2) Toyoda H, Kumada T, Tada T, et al : Erratum to : Safety and efficacy of dual directacting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 51 : 750, 2016
PubMed
3) Suda G, Kudo M, Nagasaka A, et al : Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 51 : 733-740, 2016
PubMed
4) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : C型肝炎治療ガイドライン (第5.1版). 2016
 
5) Kumada H, Chayama K, Rodrigues L Jr, et al : Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 62 : 1037-1046, 2015
 
6) ヴィキラックスインタビューフォーム P39
 
7) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : C型肝炎治療ガイドライン (第5.2版). 2016
 
P.64 掲載の参考文献
1) 日本透析医学会統計調査委員会編 : 図説わが国の慢性透析療法の現況 2007年12月31日現在. 東京 : 日本透析医学会, 2007
 
2) Ohsawa M, Kato K, Itai K, et al : Standardized prevalence ratios for chronic hepatitis C virus infection among adult Japanese hemodialysis patients. J Epidemiol 20 : 30-39, 2010
PubMed
3) 社団法人日本透析医学会 : 透析患者のC型ウイルス肝炎治療ガイドライン. 透析会誌 44 : 481-531, 2011
 
4) Suda G, Kudo M, Nagasaka A, et al : Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 51 : 733-740, 2016
PubMed
5) Toyoda H, Kumada T, Tada T, et al : Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 51 : 741-747, 2016
PubMed
6) Kikuchi K, Akiba T, Nitta K, et al : Multicenter study of pegylated interferon alpha-2a monotherapy for hepatitis C virus-infected patients on hemodialysis : REACH study. Ther Apher Dial 18 : 603-611, 2014
PubMed
7) 日本肝臓学会肝炎診療ガイドライン作成委員会 : C型肝炎治療ガイドライン (5.2版). http://www.jsh.or.jp/files/uploads/HCV_GL_ver5.2_final_Dec13.pdf
 
8) 日本透析医学会統計調査委員会編 : 図説わが国の慢性透析療法の現況 2014年12月31日現在. 東京 : 日本透析医学会, 2014
 
9) 日本透析医学会統計調査委員会編 : 図説わが国の慢性透析療法の現況 2008年12月31日現在. 東京 : 日本透析医学会, 2008
 
10) Shimokura G, Chai F, Weber DJ, et al : Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol 32 : 415-424, 2011
PubMed
11) Najafzadeh M, Andersson K, Shrank WH, et al : Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 17 : 407-419, 2015
 
12) Chahal HS, Marseille EA, Tice JA, et al : Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med 176 : 65-73, 2016
 
13) McEwan P, Ward T, Webster S, et al : Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res 46 : 423-433, 2016
PubMed
14) 医療経済評価手法の概要
 
15) Iyengar S, Tay-Teo K, Vogler S, et al : Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries : An Economic Analysis. PLoS Med 13 : e1002032, 2016
 
16) McEwan P, Ward T, Webster S, et al : Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res 46 : 423-433, 2016
PubMed
17) Igarashi A, Tang W, Guerra I, et al : Costutility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Curr Med Res Opin 33 : 11-21, 2017
PubMed

書評

最近チェックした商品履歴

Loading...